AstraZeneca's Imfinzi Debuts In Bladder Cancer With Combo Coming Soon

As many as five PD-1/L1 inhibitors will be approved for second-line metastatic disease by the end of 2017, but AstraZeneca hopes to stand apart with the combination of Imfinzi (durvalumab) with its CTLA-4 inhibitor tremelimumab.